Below you will find scientific publications authored by our members or those enabled by our platform services.
2019
Ana S. Guerreiro Stucklin, Scott Ryall
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas Journal Article
In: 2019.
Abstract | Links | BibTeX | Tags: Cancer genomics, Molecular medicine
@article{Stucklin2019,
title = {Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas},
author = {Ana S. Guerreiro Stucklin, Scott Ryall},
url = {https://www.nature.com/articles/s41467-019-12187-5#citeas},
doi = {https://doi.org/10.1038/s41467-019-12187-5},
year = {2019},
date = {2019-09-25},
abstract = {Infant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors have a higher mortality rate, while high-grade tumors have a better outcome. However, we have little understanding of their biology and therefore cannot explain this behavior nor what constitutes optimal clinical management. Here we report a comprehensive genetic analysis of an international cohort of clinically annotated infant gliomas, revealing 3 clinical subgroups. Group 1 tumors arise in the cerebral hemispheres and harbor alterations in the receptor tyrosine kinases ALK, ROS1, NTRK and MET. These are typically single-events and confer an intermediate outcome. Groups 2 and 3 gliomas harbor RAS/MAPK pathway mutations and arise in the hemispheres and midline, respectively. Group 2 tumors have excellent long-term survival, while group 3 tumors progress rapidly and do not respond well to chemoradiation. We conclude that infant gliomas comprise 3 subgroups, justifying the need for specialized therapeutic strategies.},
keywords = {Cancer genomics, Molecular medicine},
pubstate = {published},
tppubtype = {article}
}
Infant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors have a higher mortality rate, while high-grade tumors have a better outcome. However, we have little understanding of their biology and therefore cannot explain this behavior nor what constitutes optimal clinical management. Here we report a comprehensive genetic analysis of an international cohort of clinically annotated infant gliomas, revealing 3 clinical subgroups. Group 1 tumors arise in the cerebral hemispheres and harbor alterations in the receptor tyrosine kinases ALK, ROS1, NTRK and MET. These are typically single-events and confer an intermediate outcome. Groups 2 and 3 gliomas harbor RAS/MAPK pathway mutations and arise in the hemispheres and midline, respectively. Group 2 tumors have excellent long-term survival, while group 3 tumors progress rapidly and do not respond well to chemoradiation. We conclude that infant gliomas comprise 3 subgroups, justifying the need for specialized therapeutic strategies.